Could Abbott Laboratories Lose Strenght? Option Traders Don’t Think So


 Could Abbott Laboratories Lose Strenght? Option Traders Don't Think So

In today’s session Abbott Laboratories (ABT) registered an unusually high (1,229) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious ABT increase. With 1,229 contracts traded and 26524 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: ABT161118C00043000 closed last at: $0.96 or 45.5% up. About 5.86 million shares traded hands. Abbott Laboratories (NYSE:ABT) has risen 8.19% since March 1, 2016 and is uptrending. It has underperformed by 1.06% the S&P500.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on October, 19. They expect $0.58 EPS, up 7.41% or $0.04 from last year’s $0.54 per share. ABT’s profit will be $855.44 million for 18.20 P/E if the $0.58 EPS becomes a reality. After $0.55 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 5.45% EPS growth.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Out of 16 analysts covering Abbott Laboratories (NYSE:ABT), 9 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 56% are positive. $90 is the highest target while $9 is the lowest. The $48.83 average target is 15.66% above today’s ($42.22) stock price. Abbott Laboratories has been the topic of 40 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Thursday, July 23 by RBC Capital Markets. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Stifel Nicolaus on Thursday, July 23. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Monday, December 7 by Jefferies. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Tuesday, March 15 by Jefferies. The stock has “Neutral” rating given by Goldman Sachs on Friday, November 13. Jefferies maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, July 14. Jefferies has “Buy” rating and $49 price target. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Tuesday, June 21 by Edward Jones. Deutsche Bank maintained the stock with “Buy” rating in Saturday, August 29 report. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Thursday, August 27 by Wells Fargo. As per Saturday, August 29, the company rating was maintained by BTIG Research.

Insitutional Activity: The institutional sentiment increased to 1.05 in 2016 Q2. Its up 0.18, from 0.87 in 2016Q1. The ratio is positive, as 68 funds sold all Abbott Laboratories shares owned while 488 reduced positions. 79 funds bought stakes while 507 increased positions. They now own 1.05 billion shares or 2.91% more from 1.02 billion shares in 2016Q1.
Kcm Investment Advsrs Limited Liability Company holds 0.61% or 221,360 shares in its portfolio. Moreover, Meag Munich Ergo Kapitalanlagegesellschaft Mbh has 0.05% invested in Abbott Laboratories (NYSE:ABT) for 13,600 shares. Old Mutual Customised Solutions (Proprietary) Ltd has 13,600 shares for 0.13% of their US portfolio. Burns J W & Ny, a New York-based fund reported 20,065 shares. Nelson Van Denburg & Campbell Wealth Mngmt Gp Llc holds 0% of its portfolio in Abbott Laboratories (NYSE:ABT) for 206 shares. Gabelli Funds Ltd Liability Corp has invested 0.05% of its portfolio in Abbott Laboratories (NYSE:ABT). Hm Payson accumulated 846,141 shares or 1.66% of the stock. Pacwest Fin Management accumulated 0.59% or 24,075 shares. Gam Hldgs Ag accumulated 0.24% or 392,098 shares. Cincinnati Specialty Underwriters Insur accumulated 27,200 shares or 1.28% of the stock. The California-based Agran Libbie has invested 0.4% in Abbott Laboratories (NYSE:ABT). Gsa Limited Liability Partnership reported 83,271 shares or 0.18% of all its holdings. Advisor Prtnrs Ltd has invested 0.27% of its portfolio in Abbott Laboratories (NYSE:ABT). Dodge And Cox owns 29,268 shares or 0% of their US portfolio. First Foundation Advsr has invested 0.03% of its portfolio in Abbott Laboratories (NYSE:ABT).

Insider Transactions: Since April 28, 2016, the stock had 1 insider purchase, and 8 insider sales for $6.08 million net activity. NATH DEEPAK S. had sold 53 shares worth $2,189. $22,312 worth of Abbott Laboratories (NYSE:ABT) shares were sold by YOOR BRIAN B. Shares for $1.17M were sold by Warmuth Michael J on Tuesday, July 26. Shares for $126,276 were sold by ALLEN HUBERT L on Tuesday, June 28. The insider Funck Robert E sold 26,800 shares worth $1.15M. Watkin Jared also sold $20,770 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, June 15. Shares for $33,994 were sold by Salvadori Daniel Gesua Sive.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The company has a market cap of $62.27 billion. The Firm operates in four business divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 32.32 P/E ratio. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply